People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Garvey’s career spans decades of influential work, shaping national guidelines for obesity and diabetes treatment.